[stock_market_widget type=”leaderboard” template=”color-background” color=”red” assets=”2616.HK” api=”yf”]
CStone Pharmaceuticals
Description: CStone Pharmaceuticals, a clinical-stage biotechnology company, focuses on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The company has a licensing agreement with Numab Therapeutics AG and a clinical collaboration with Bayer HealthCare LLC.
Industry: Biotechnology
Founded Year : 2015
Headquarter : Shanghai, People’s Republic of China
Website: http://www.cstonepharma.com
Phone: 86 21 6109 7678
[stock_market_widget type=”leaderboard” template=”color-background” color=”red” assets=”2696.HK” api=”yf”]
Shanghai Henlius Biotech, Inc.
Description: Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologics with a focus on oncology and autoimmune diseases worldwide. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.
Industry: Biotechnology
Founded Year : 2010
Headquarter : Beijing, People’s Republic of China
Website: http://www.henlius.com
Phone: 86 21 3339 5800
[stock_market_widget type=”leaderboard” template=”color-background” color=”red” assets=”1877.HK” api=”yf”]
Shanghai Junshi Biosciences Co., Ltd.
Description: Shanghai Junshi Biosciences Co., Ltd., a bio-pharmaceutical company, engages in the research, discovery, and development of various biologic drug candidates in the People’s Republic of China. Shanghai Junshi Biosciences Co., Ltd. has a clinical study cooperation agreement with Betta Pharmaceuticals Co., Ltd.; a co-development and strategic collaboration agreement CSPC Pharmaceutical Group Limited; a strategic collaboration with Ascentage Pharma Group Corp. Ltd.; and a drug combination clinical research cooperation agreement with Suzhou Sinovent Pharmaceuticals Co., Ltd. The company also has a collaboration agreement with I-Mab Biopharma to evaluate the combination therapy of I-Mab’s TJD5, a proprietary CD73 antibody with Junshi Biosciences’s Toripalimab, a recombinant humanized anti-PD-1 monoclonal antibody in patients with cancers in China.
Industry: Biotechnology
Founded Year : 2012
Headquarter : Shanghai, People’s Republic of China
Website: http://junshipharma.com
Phone: 86 21 6105 8800
[stock_market_widget type=”leaderboard” template=”color-background” color=”blue” assets=”BOLD” api=”yf”]
Audentes Therapeutics, Inc.
Description: Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar.
Industry: Biotechnology
Founded Year : 2012
Headquarter : San Francisco, CA, USA
Website: http://www.audentestx.com
Phone: 415-818-1001
No comment yet, add your voice below!